Alpenglow Biosciences and Partners Secure a Total of $24M for Development of Alpenglow’s 3D Spatial Pathology Platform

Share:

Alpenglow Biosciences, a leading 3D spatial biology company, was recently awarded contracts from Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH) and secured additional investment to further its clinical product development.

ARPA-H has awarded Jonathan T.C. Liu, Ph.D., University of Washington Professor and Scientific Co-Founder of Alpenglow Biosciences, a groundbreaking contract to develop a platform technology for precision tumor removal. The five-year ARPA-H contract (up to $21M) is part of the Cancer Moonshot initiative spearheaded by the Biden administration. Alpenglow, alongside elite academic medical centers, is set to transform the fight against cancer with its innovative AI-driven 3D Spatial Biology platform.

Share: